CALGARY, ALBERTA–(Marketwired – Sept. 9, 2016) – Hemostemix Inc. (“Hemostemix” or the “Company“) (TSX VENTURE:HEM)(OTCQX:HMTXF) announces the results from its 2016 Annual and Special Meeting of Shareholders. At the meeting, the shareholders approved fixing the number of directors at four, elected the following to serve as board members until the next annual election of directors: Robert J. Bard, Robert L. Buckler, Angus Jenkins and Victor Redekop and approved the appointment of MNP LLP, as the Company’s auditor for the ensuing year. In addition, the rolling Stock Option Plan, the Advanced Notice By-law and the Enhanced Quorum By-law were approved.
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The phase 2 trial targets a participant’s diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. The Company recently received FDA clearance to commence clinical trials in the United States.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM and on the OTCQX® Best Market under the trading symbol HMTXF. For more information, visit hemostemix.com or email [email protected].
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined under the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” and similar expressions, or that events or conditions “will,” “would,” “may,” “could,” or “should” occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
